CUE Latest Press Releases

-- September 20, 2026 --

Cue Biopharma Announces Positive Topline Results from CUE-221 Phase 2 Study in Chronic Spontaneous Urticaria Globe Newswire 6:00 AM

-- August 24, 2026 --

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Cue Biopharma, Inc. (NASDAQ: CUE) PRNewswire 9:05 AM

-- August 14, 2026 --

Cue Biopharma Reports Second Quarter 2026 Financial Results and Recent Business Highlights Globe Newswire 4:05 PM

-- August 3, 2026 --

Cue Biopharma Announces Appointment of James M. Ahlers as Chief Financial Officer and CUE-221 Investigational New Drug Submission Globe Newswire 8:30 AM

-- July 13, 2026 --

Cue Biopharma Appoints Dominic Borie, M.D., Ph.D., as Chief Medical Officer and Head of Research & Development Globe Newswire 8:30 AM

-- July 9, 2026 --

Cue Biopharma Announces $50.0 Million Private Placement Globe Newswire 9:40 PM

-- June 2, 2026 --

Cue Biopharma Announces Board Transition and Addition of New Directors with Continued Company Evolution Globe Newswire 4:05 PM

-- May 21, 2026 --

Cue Biopharma to Present at the 2026 Jefferies Global Healthcare Conference Globe Newswire 4:05 PM

-- May 14, 2026 --

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments Globe Newswire 4:07 PM

Market Data Delayed 15 Minutes

Questions? Feedback?Olark live chat software